Vizsgálati helyszín
UP Health System Marquette
Marquette, Michigan 49855, Egyesült ÁllamokMég nincs intézményhez kötve
- 14futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Lezárult3 vizsgálat
- Toboroz2 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)10 vizsgálat
- NRG Oncology3 vizsgálat
- Alliance for Clinical Trials in Oncology1 vizsgálat
- ECOG-ACRIN Cancer Research Group1 vizsgálat
- Medtronic1 vizsgálat
- és még 1
Futó vizsgálatok
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Eric Schaff (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Sheetal S. Acharya (principal investigator)
Fut, nem toboroz
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943· Medtronic· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
NCT00843882· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· 3. fázis· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek